Patents by Inventor Markus Weigandt
Markus Weigandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240408021Abstract: The present invention relates to a pharmaceutical formulation of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof, as well as a method of making same, as well as medical uses thereof.Type: ApplicationFiled: August 21, 2024Publication date: December 12, 2024Applicant: Merck Patent GmbHInventors: Simon Geissler, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
-
Publication number: 20230119567Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 1, 2022Publication date: April 20, 2023Applicant: Merck Patent GmbHInventors: Simon Geissler, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
-
Publication number: 20230043290Abstract: The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGF?RII (such as an anti-PD-L1:TGF?-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments.Type: ApplicationFiled: December 21, 2020Publication date: February 9, 2023Applicants: ARES TRADING S.A., GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LTD.Inventors: Chiara IORIO, Carlo PERGOLA, Fabiana CANAL, Gianluca RINALDI, Katrin GRIESER, Markus WEIGANDT, Matthias WINZER
-
Patent number: 11559490Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.Type: GrantFiled: March 28, 2018Date of Patent: January 24, 2023Assignee: Merck Patent GmbHInventors: Simon Geissler, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
-
Patent number: 11478459Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.Type: GrantFiled: August 8, 2018Date of Patent: October 25, 2022Assignee: Merck Patent GmbHInventors: Simon Geissler, Stefan Schiller, Meike Harms, Holger Kubas, Markus Weigandt, Michael Lange
-
Publication number: 20220288068Abstract: The present invention relates to a solid pharmaceutical preparation of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile, a method of making same, and medical uses thereof.Type: ApplicationFiled: July 8, 2020Publication date: September 15, 2022Applicant: MERCK PATENT GMBHInventors: Corinna SCHOCH, Markus RIEHL, Gero HOOFF, Markus KLEMM, Carsten SCHMIDT, Markus WEIGANDT
-
Patent number: 11058769Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.Type: GrantFiled: December 5, 2016Date of Patent: July 13, 2021Assignees: MERCK PATENT GMBH, PFIZER INC.Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
-
Publication number: 20210100903Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.Type: ApplicationFiled: December 9, 2020Publication date: April 8, 2021Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
-
Publication number: 20210085611Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-tnorpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 28, 2018Publication date: March 25, 2021Applicant: Merck Patent GmbHInventors: Simon GEISSLER, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
-
Publication number: 20200237733Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.Type: ApplicationFiled: August 8, 2018Publication date: July 30, 2020Applicant: Merck Patent GmbHInventors: Simon GEISSLER, Stefan SCHILLER, Meike HARMS, Holger KUBAS, Markus WEIGANDT, Michael LANGE
-
Patent number: 10561733Abstract: The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.Type: GrantFiled: February 11, 2013Date of Patent: February 18, 2020Assignee: Merck Patent GmbHInventors: Markus Weigandt, Senta Voss, Tobias Miller, Achim Goepferich
-
Patent number: 10561622Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).Type: GrantFiled: October 15, 2015Date of Patent: February 18, 2020Assignee: Merck Patent GmbHInventors: Andrea Hanefeld, Markus Weigandt, Stefan Schiller, Marc Schneider, Michael C. Lehr
-
Patent number: 10369217Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.Type: GrantFiled: May 12, 2015Date of Patent: August 6, 2019Assignee: MERCK PATENT GMBHInventors: Andrea Hanefeld, Markus Weigandt, Michael Wolf, Percy Knolle, Matthias Schroeder, Regina Scherliess, Peter Walden, Andrea Diedrich, Hartwig Steckel, Renato Brito Baleeiro
-
Publication number: 20180369377Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.Type: ApplicationFiled: December 5, 2016Publication date: December 27, 2018Applicants: MERCK PATENT GmbH, PFIZER INC.Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
-
Patent number: 10111952Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: GrantFiled: October 6, 2017Date of Patent: October 30, 2018Assignee: MERCK PATENT GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Publication number: 20180071386Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: ApplicationFiled: October 6, 2017Publication date: March 15, 2018Applicant: Merck Patent GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Patent number: 9808521Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.Type: GrantFiled: June 30, 2016Date of Patent: November 7, 2017Assignee: MERCK PATENT GMBHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Publication number: 20170312229Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).Type: ApplicationFiled: October 15, 2015Publication date: November 2, 2017Applicant: Merck Patent GmbHInventors: Andrea HANEFELD, Markus WEIGANDT, Stefan SCHILLER, Marc SCHNEIDER, Michael C. LEHR
-
Publication number: 20170143822Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.Type: ApplicationFiled: May 12, 2015Publication date: May 25, 2017Applicant: MERCK PATENT GMBHInventors: Andrea HANEFELD, Markus WEIGANDT, Michael WOLF, Percy KNOLLE, Matthias SCHROEDER, Regina SCHERLIESS, Peter WALDEN, Andrea DIEDRICH, Hartwig STECKEL, Renato Brito BALEEIRO
-
Publication number: 20160303228Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: ApplicationFiled: June 30, 2016Publication date: October 20, 2016Applicant: Merck Patent GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig